Business Context and Reporting Period
This Form 8-K is filed by Eyenovia, Inc. (not Hyperion Defi, Inc.) on May 16, 2024. The report addresses corporate actions regarding the company's At-The-Market (ATM) equity offering program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on legal and procedural updates rather than financial performance data.
Material Changes
- ATM Program Suspension: On April 8, 2024, the company notified Leerink Partners LLC of the suspension and termination of the existing ATM Prospectus Supplement related to its Sales Agreement dated December 14, 2021.
- ATM Program Resumption: On May 16, 2024, the company announced its intent to resume sales of common stock under the Sales Agreement.
- Regulatory Filing: The company is filing a new prospectus supplement to its Form S-3 registration statement (File No. 333-261638) to facilitate the resumption of sales.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking outlook statements, or a discussion of general business risks. The primary focus is the procedural resumption of the equity offering. The company has attached a legal opinion from Covington & Burling LLP regarding the validity of the ATM Shares as Exhibit 5.1.
Investor Verification Checklist
- Verify the status of the new prospectus supplement filed under Form S-3 (File No. 333-261638).
- Confirm the terms of the Sales Agreement with Leerink Partners LLC remain in full force and effect.
- Review the attached legal opinion (Exhibit 5.1) from Covington & Burling LLP regarding the validity of the shares to be issued.
- Note that the registrant name in the filing is Eyenovia, Inc., trading under the symbol EYEN on the Nasdaq Capital Market.